{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:29:54Z","timestamp":1788420594287,"version":"build-2803163510"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,24]],"date-time":"2026-02-24T00:00:00Z","timestamp":1771891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinejcf.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cardiac Failure"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.cardfail.2026.02.016","type":"journal-article","created":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T22:03:44Z","timestamp":1772575424000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The Association of Guideline-Directed Medical Therapy Scores and Patient Outcomes in Patients With Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6754-3670","authenticated-orcid":false,"given":"TREJEEVE","family":"MARTYN","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MICHEL","family":"CHEDID\u202fEL\u202fHELOU","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ZIAD","family":"ZALAQUETT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JUDAH","family":"RAJENDRAN","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HARSH","family":"PATOLIA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"NANCY M.","family":"ALBERT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ANKEET","family":"BHATT","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JAVED","family":"BUTLER","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HUNTER","family":"BLOCK-BEACH","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SAMIR","family":"KAPADIA","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"AMANDA","family":"VEST","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W. H. WILSON","family":"TANG","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JERRY D.","family":"ESTEP","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"RANDALL C.","family":"STARLING","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cardfail.2026.02.016_bib0001","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2026.02.016_bib0002","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.cardfail.2026.02.016_bib0003","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1002\/ejhf.3067","article-title":"The utilization and impact of cardiovascular specialists on guideline-directed medical scores: an analysis of a diverse, multi-state, electronic health record-based registry","volume":"25","author":"Martyn","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2026.02.016_bib0004","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jchf.2020.08.016","article-title":"Putting the \u201coptimal\u201d in optimal medical therapy","volume":"9","author":"DeFilippis","year":"2021","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2026.02.016_bib0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2023.04.019","article-title":"Angiotensin-neprilysin inhibition in patients with mildly reduced or preserved ejection fraction and worsening heart failure","volume":"82","author":"Mentz","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.02.016_bib0006","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.02.016_bib0007","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"Angiotensin\u2013neprilysin inhibition in heart failure with preserved ejection fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.02.016_bib0008","first-page":"352","volume":"23","author":"Bozkurt","year":"2021","journal-title":"J Card Fail"},{"key":"10.1016\/j.cardfail.2026.02.016_bib0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2022.08.009","article-title":"Heart failure drug treatment-inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF)","volume":"11","author":"Savarese","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2026.02.016_bib0010","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(20)30748-0","article-title":"Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: a comparative analysis of three randomised controlled trials","volume":"396","author":"Vaduganathan","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.cardfail.2026.02.016_bib0011","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1002\/ejhf.70074","article-title":"Contemporary medical therapy for heart failure across the ejection fraction spectrum: the OPTIPHARM-HF registry","volume":"27","author":"Inciardi","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2026.02.016_bib0012","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1002\/ejhf.70006","article-title":"Real-life implementation of guideline-recommended medical therapy in heart failure with reduced ejection fraction: effects on prognosis and left ventricular ejection fraction. Primary results of TITRATE-HF","volume":"27","author":"Malgie","year":"2025","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cardfail.2026.02.016_bib0013","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.123.011164","article-title":"Generalizable approach to quantifying guideline-directed medical therapy","volume":"17","author":"Khan","year":"2024","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.cardfail.2026.02.016_bib0014","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jacc.2025.05.040","article-title":"Guideline-directed medical therapy and outcomes among patients with heart failure with improved ejection fraction","volume":"86","author":"Min","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.02.016_bib0015","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.jchf.2022.03.009","article-title":"Effects of dapagliflozin according to the Heart Failure Collaboratory medical therapy score: insights from DAPA-HF","volume":"10","author":"Butt","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2026.02.016_bib0016","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jacc.2021.11.033","article-title":"Optimal background pharmacological therapy for heart failure patients in clinical trials: JACC Review Topic of the Week","volume":"79","author":"Fiuzat","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.02.016_bib0017","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1056\/NEJMoa2407107","article-title":"Finerenone in heart failure with mildly reduced or preserved ejection fraction","volume":"391","author":"Solomon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.02.016_bib0018","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/eurheartj\/ehz158","article-title":"The continuous heart failure spectrum: moving beyond an ejection fraction classification","volume":"40","author":"Triposkiadis","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2026.02.016_bib0019","article-title":"Assessing medical therapy optimization in cardiovascular-kidney-metabolic clinical trials: an initiative from the Heart Failure Collaboratory","author":"Bhatt","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2026.02.016_bib0020","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.jchf.2024.11.023","article-title":"Severe heart failure and treatment with dapagliflozin across the ejection fraction spectrum: DAPA-HF and DELIVER","volume":"13","author":"Inciardi","year":"2025","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2026.02.016_bib0021","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1016\/j.jacc.2024.01.027","article-title":"Sacubitril\/valsartan in patients hospitalized with decompensated heart failure","volume":"83","author":"Morrow","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cardfail.2026.02.016_bib0022","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1093\/eurheartj\/ehad344","article-title":"Sacubitril\/valsartan in heart failure with mildly reduced or preserved ejection fraction: a pre-specified participant-level pooled analysis of PARAGLIDE-HF and PARAGON-HF","volume":"44","author":"Vaduganathan","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cardfail.2026.02.016_bib0023","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/s41591-022-01971-4","article-title":"Dapagliflozin across the range of ejection fraction in patients with heart failure: a patient-level, pooled meta-analysis of DAPA-HF and DELIVER","volume":"28","author":"Jhund","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.cardfail.2026.02.016_bib0024","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":". Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cardfail.2026.02.016_bib0025","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.jchf.2023.03.017","article-title":"Beta-blocker use and heart failure outcomes in mildly reduced and preserved ejection fraction","volume":"11","author":"Arnold","year":"2023","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.cardfail.2026.02.016_bib0026","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1001\/jamacardio.2023.5500","article-title":"\u03b2-blocker withdrawal and functional capacity improvement in patients with heart failure with preserved ejection fraction","volume":"9","author":"Palau","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.cardfail.2026.02.016_bib0027","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1056\/NEJMoa2504735","article-title":"Beta-blockers after myocardial infarction without reduced ejection fraction","volume":"393","author":"Ibanez","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Journal of Cardiac Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916426000850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1071916426000850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T20:29:51Z","timestamp":1772742591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1071916426000850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":27,"alternative-id":["S1071916426000850"],"URL":"https:\/\/doi.org\/10.1016\/j.cardfail.2026.02.016","relation":{},"ISSN":["1071-9164"],"issn-type":[{"value":"1071-9164","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Association of Guideline-Directed Medical Therapy Scores and Patient Outcomes in Patients With Heart Failure Across the Spectrum of Left Ventricular Ejection Fraction","name":"articletitle","label":"Article Title"},{"value":"Journal of Cardiac Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cardfail.2026.02.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}